SpliceBio has become the biotechnology company that has raised the most money in the history of the sector in Spain. From its laboratories in the Barcelona Science Park (PCB), the Catalan company has raised €119 million. in a financing round which will be used to validate the gene therapy he has developed for a rare disease that causes blindness. More than ten years ago, the company was born from the research conducted by Miquel Vila-Perelló and Silvia Frutos in the United States, under the leadership of Professor Tom Muir, a pioneer in protein modification that allows them to attack Stargardt disease. With a workforce of more than 40 employees, the company grew alongside the local biotechnology sector, which set another investment record this first half of the year with €227 million, according to data from Biocat.

Catalan biotech company SpliceBio has closed a $135 million (€119 million at the current exchange rate) financing round, the largest ever by a Catalan company in the sector, according to sources at the company who spoke to ARA.